Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 881-892

  Martorelli, Debora ^a   Coppotelli, Giuseppe ^b   Muraro, Elena ^a   Dolcetti, Riccardo ^a   Masucci, Maria G ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dendritic cell; Epitope choice; Gly Ala repeat; Idiotype vaccine

Indexed keywords

CANCER VACCINE; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN 1; GLYCINE ALANINE REPEAT DOMAIN OF THE EPSTEIN BARR VIRUS ANTIGEN 1; IDIOTYPE VACCINE; IDIOTYPIC ANTIBODY; IGKV 3 20; IMMUNOGLOBULIN IDIOTYPE; LENTIVIRUS VECTOR; PEPTIDE; PROTEASOME; PROTEIN; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BLAST CELL; CD4+ CD8+ T LYMPHOCYTE; CELL MATURATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEGRADATION; DENDRITIC CELL; DRUG DEGRADATION; DRUG EFFICACY; EFFECTOR CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYSOSOME; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR CELL LINE; VACCINE PRODUCTION;

CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LENTIVIRUS; LYSOSOMES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84862339352     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1157-5     Document Type: Article

References (53)

1. Palucka K, Banchereau J, Mellman I (2010) Designing vaccines based on biology of human dendritic cell subsets. Immunity 33(4):464-478
2. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK (2008) CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 223:391-421 (Pubitemid 351986179)
3. Nencioni A, Grunebach F, Schmidt SM, Muller MR, Boy D, Patrone F, Ballestrero A, Brossart P (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65(3):191-199 (Pubitemid 351200461)
4. Palucka AK, Ueno H, Fay J, Banchereau J (2008) Dendritic cells: a critical player in cancer therapy? J Immunother 31(9):793-805
5. Harzstark AL, Small EJ (2008) Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc) 44(4):271-278 (Pubitemid 351897260)
6. Schuetz F, Ehlert K, Ge Y, Schneeweiss A, Rom J, Inzkirweli N, Sohn C, Schirrmacher V, Beckhove P (2009) Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 58(6):887-900
7. Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D (2003) Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant 3(11):1369-1377 (Pubitemid 37288081)
8. Dauer M, Schad K, Junkmann J, Bauer C, Herten J, Kiefl R, Schnurr M, Endres S, Eigler A (2006) IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J Leukoc Biol 80(2):278-286 (Pubitemid 44835501)
9. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169(1):350-358 (Pubitemid 34686155)
10. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF (2009) Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 7:109
11. Norder M, Becker PD, Drexler I, Link C, Erfle V, Guzman CA Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One 5(6):e11400
12. Delamarre L, Couture R, Mellman I, Trombetta ES (2006) Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 203(9):2049-2055. doi:10.1084/jem.20052442 (Pubitemid 44352226)
13. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES (2005) Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307(5715):1630-1634. doi: 10.1126/science.1108003 (Pubitemid 40354746)
14. Monaco JJ (1995) Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 57(4):543-547
15. Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM (2007) Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 139(3):415-424 (Pubitemid 47512192)
16. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R (2009) Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 50(1):37-46
17. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. doi:10.1200/JCO.2010.33.3005
18. de Re V, Simula MP, Pavan A, Garziera M, Marin D, Dolcetti R, de Vita S, Sansonno D, Geremia S, Toffoli G (2009) Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations. Ann N Y Acad Sci 1173:152-160
19. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG (1998) Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91(7):2433-2442 (Pubitemid 28155518)
20. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M (2000) Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96(10):3578-3584
21. De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G, Boiocchi M (2002) Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 32(3):903-910 (Pubitemid 34257568)
22. Shokri F, Mageed RA, Jefferis R, Kitas GD, Katsikis P, Moutsopoulos HM (1989) Monoclonal anti-cross-reactive idiotype antibodies as possible probes for lymphoproliferation in primary Sjogren's syndrome. Br J Rheumatol 28(5):458-459
23. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wundisch T, Neubauer A, Renner C, Falkow S, Muller A Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 115(3):581-591
24. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wundisch T, Neubauer A, Renner C, Falkow S, Muller A (2010) Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 115(3):581-591
25. Smilevska T, Tsakou E, Hadzidimitriou A, Bikos V, Stavroyianni N, Laoutaris N, Fassas A, Alphanagnostopoulos A, Papadaki T, Belessi C, Stamatopoulos K (2008) Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma. Blood Cells Mol Dis 41(2):215-218
26. Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K, Enblad G, Merup M, Vilpo J, Juliusson G, Sundstrom C, Soderberg O, Roos G, Rosenquist R (2004) Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 104(9):2879-2885 (Pubitemid 39434975)
27. Stamatopoulos K, Belessi C, Hadzidimitriou A, Smilevska T, Kalagiakou E, Hatzi K, Stavroyianni N, Athanasiadou A, Tsompanakou A, Papadaki T, Kokkini G, Paterakis G, Saloum R, Laoutaris N, Anagnostopoulos A, Fassas A (2005) Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 106(10):3575-3583 (Pubitemid 41609196)
28. Buonaguro L, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L, Sousa V, De Re V, Dolcetti R, Buonaguro FM (2010) Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med 8:18. doi:10.1186/1479-5876-8-18
29. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375(6533):685-688
30. Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG (1998) A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 4(8):939-944 (Pubitemid 28364034)
31. Coppotelli G, Mughal N, Marescotti D, Masucci MG (2011) High avidity binding to DNA protects ubiquitylated substrates from proteasomal degradation. J Biol Chem 286(22):19565-19575
32. Dantuma NP, Heessen S, Lindsten K, Jellne M, Masucci MG (2000) Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci USA 97(15):8381-8385 (Pubitemid 30639681)
33. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. Rna 9(4):493-501 (Pubitemid 36356735)
34. Emanuel BS, Cannizzaro L, Ornstein-Goldstein N, Indik ZK, Yoon K, May M, Oliver L, Boyd C, Rosenbloom J (1985) Chromosomal localization of the human elastin gene. Am J Hum Genet 37(5):873-882 (Pubitemid 16224127)
35. Crook T, Parker GA, Rozycka M, Crossland S, Allday MJ (1998) A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear: cytoplasmic shuttling defect. Oncogene 16(11):1429-1441 (Pubitemid 28151850)
36. Abe M, Nozawa Y, Wakasa H, Ohno H, Fukuhara S (1988) Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer 61(3):483-490 (Pubitemid 18039362)
37. Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F (1976) Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 18(4): 421-431
38. Caggiari L, Cannizzaro R, De Zorzi M, Canzonieri V, Da Ponte A, De Re V (2008) A new HLA-A*680106 allele identified in individuals with celiac disease from the Friuli area of northeast Italy. Tissue Antigens 72(5):491-492
39. De Re V, Caggiari L, Monti G, Libra M, Spina M, Dolcetti R, De Zorzi M, Racanelli V, Crovatto M, Toffoli G (2010) HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens 75(2):127-135
40. Carlsson B, Cheng WS, Totterman TH, Essand M (2003) Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 121(3):428-438 (Pubitemid 36628334)
41. Roden MM, Lee KH, Panelli MC, Marincola FM (1999) A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 226(1-2): 29-41 (Pubitemid 29336528)
42. Perret R, Ronchese F (2008) Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 72(3):187-194
43. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708-712
44. Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR (2011) Idiotype vaccine strategies for treatment of follicular lymphoma. Future Oncol 7(1):111-122
45. Zhang M, Coffino P (2004) Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing. J Biol Chem 279(10):8635-8641 (Pubitemid 38295918)
46. Apcher S, Komarova A, Daskalogianni C, Yin Y, Malbert-Colas L, Fahraeus R (2009) mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. J Virol 83(3):1289-1298
47. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199(4):459-470 (Pubitemid 38233830)
48. Hammer D, Wild J, Ludwig C, Asbach B, Notka F, Wagner R (2008) Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo. Hum Gene Ther 19(6):622-634 (Pubitemid 351913524)
49. Chemali M, Radtke K, Desjardins M, English L (2011) Alternative pathways for MHC class I presentation: a new function for autophagy. Cell Mol Life Sci 68(9):1533-1541
50. English L, Chemali M, Duron J, Rondeau C, Laplante A, Gingras D, Alexander D, Leib D, Norbury C, Lippe R, Desjardins M (2009) Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 10(5):480-487
51. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307(5709): 593-596 (Pubitemid 40165684)
52. Breckpot K, Emeagi PU, Thielemans K (2008) Lentiviral vectors for anti-tumor immunotherapy. Curr Gene Ther 8(6):438-448
53. Grabski E, Waibler Z, Schule S, Kloke BP, Sender LY, Panitz S, Cichutek K, Schweizer M, Kalinke U (2011) Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems. Mol Biotechnol 47(3):262-269